MLICM
PRVB

Metropolitan Life Insurance Company (MetLife)’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,514
Closed -$84.7K – 2556
2023
Q1 		$84.7K Sell
3,514
-75
-2% -$941 ﹤0.01% 1092
2022
Q4 		$37.9K Hold
3,589
– – ﹤0.01% 1639
2022
Q3 		$16.2K Buy
3,589
+2,447
+214% +$11.2K ﹤0.01% 2123
2022
Q2 		$4.57K Sell
1,142
-2,728
-70% -$12.9K ﹤0.01% 2345
2022
Q1 		$28.3K Sell
3,870
-1,411
-27% -$8.44K ﹤0.01% 1923
2021
Q4 		$29.7K Sell
5,281
-1,243
-19% -$7.89K ﹤0.01% 2737
2021
Q3 		$41.8K Sell
6,524
-7,257
-53% -$46.6K ﹤0.01% 2784
2021
Q2 		$116K Buy
13,781
+1,525
+12% +$12.3K ﹤0.01% 2518
2021
Q1 		$129K Sell
12,256
-1,297
-10% -$18.3K ﹤0.01% 2310
2020
Q4 		$230K Hold
13,553
– – ﹤0.01% 1841
2020
Q3 		$174K Hold
13,553
– – ﹤0.01% 1859
2020
Q2 		$191K Buy
+13,553
New +$171K ﹤0.01% 1827

Other funds holding PRVB

UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s PRVB Position: Q2 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 3,514 shares — an estimated $84.7K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in PRVB in Q2 2020 and held it in 12 quarters. The position peaked at $230K in Q4 2020. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 3,514 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $84.7K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Provention Bio, Inc. Common Stock in Q2 2020 and held it in 12 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Provention Bio, Inc. Common Stock position peaked at $230K in Q4 2020.
  • 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2023, filed 10 Aug 2023.